Oyster Point Pharma acquired by Viatris
Viatris acquired Oyster Point Pharma, an ophthalmic pharmaceuticals brand, on Jan 3, 2023.
Transaction summary
- Target
- Oyster Point Pharma
- Acquirer
- Viatris
- Seller
- -
- Announced
- 2022-11-07
- Completed
- 2023-01-03
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-10-21
Value and multiples
100% enterprise value
Undisclosed
Value not disclosed
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
20.7x
EBITDA basis not stated
Basis: FundComb estimate
Basis
- The 20.7x EBITDA multiple comes from FundComb’s comps spreadsheet and is not confirmed by a public source; the price, EBITDA amount and period behind it are not stated. Viatris announced that it closed the acquisition of Oyster Point Pharma on 3 January 2023 (PR Newswire).
Source summary
Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division - PR Newswire
ConfirmedContinue your research
Related transaction comps
Biotech
ITM Isotope Technologies Munich SE acquired by Telix Pharmaceuticals Limited
2026-09-20 · Confirmed
View transaction → BiotechAtaiBeckley acquired by Eli Lilly and Company
2026-09-11 · Confirmed
View transaction → BiotechDersimelagon rights acquired by LEO Pharma
2026-08-18 · Confirmed
View transaction → BiotechEdgewise Therapeutics' Muscular Dystrophy Business acquired by Servier
2026-07-13 · Confirmed
View transaction →